BACKGROUND: Adjuvanted vaccines have the potential to improve influenza pandemic response. AS03 adjuvant has been shown to enhance the immune response to inactivated influenza vaccines. METHODS: This trial was designed to evaluate the immunogenicity and safety of an inactivated 2009 H1N1 influenza vaccine at varying dosages of hemagglutinin with and without extemporaneously mixed AS03 adjuvant system in adults ≥ 18 years of age. Adults were randomized to receive 2 doses of 1 of 5 vaccine formulations (3.75 µg, 7.5 µg, or 15 µg with AS03 or 7.5 µg or 15 µg without adjuvant). RESULTS: The study population included 544 persons <65 years of age and 245 persons ≥ 65 years of age. Local adverse events tended to be more frequent in the adjuvanted vaccine groups, but severe reactions were uncommon. In both age groups, hemagglutination inhibition antibody geometric mean titers after dose one were higher in the adjuvanted groups, compared with the 15 µg unadjuvanted group, and this difference was statistically significant for the comparison of the 15 µg adjuvanted group with the 15 µg unadjuvanted group. CONCLUSIONS:AS03 adjuvant system improves the immune response to inactivated 2009 H1N1 influenza vaccine in both younger and older adults and is generally well tolerated. ClinicalTrials.gov NCT00963157.
RCT Entities:
BACKGROUND: Adjuvanted vaccines have the potential to improve influenza pandemic response. AS03 adjuvant has been shown to enhance the immune response to inactivated influenza vaccines. METHODS: This trial was designed to evaluate the immunogenicity and safety of an inactivated 2009 H1N1 influenza vaccine at varying dosages of hemagglutinin with and without extemporaneously mixed AS03 adjuvant system in adults ≥ 18 years of age. Adults were randomized to receive 2 doses of 1 of 5 vaccine formulations (3.75 µg, 7.5 µg, or 15 µg with AS03 or 7.5 µg or 15 µg without adjuvant). RESULTS: The study population included 544 persons <65 years of age and 245 persons ≥ 65 years of age. Local adverse events tended to be more frequent in the adjuvanted vaccine groups, but severe reactions were uncommon. In both age groups, hemagglutination inhibition antibody geometric mean titers after dose one were higher in the adjuvanted groups, compared with the 15 µg unadjuvanted group, and this difference was statistically significant for the comparison of the 15 µg adjuvanted group with the 15 µg unadjuvanted group. CONCLUSIONS:AS03 adjuvant system improves the immune response to inactivated 2009 H1N1 influenza vaccine in both younger and older adults and is generally well tolerated. ClinicalTrials.gov NCT00963157.
Authors: Daniel Wai-Sing Chu; Shinn-Jang Hwang; Fong Seng Lim; Helen May Lin Oh; Prasert Thongcharoen; Pan-Chyr Yang; Hans L Bock; Mamadou Dramé; Paul Gillard; Yanee Hutagalung; Haiwen Tang; Yee Leong Teoh; Ripley W Ballou Journal: Vaccine Date: 2009-08-13 Impact factor: 3.641
Authors: Michael E Greenberg; Michael H Lai; Gunter F Hartel; Christine H Wichems; Charmaine Gittleson; Jillian Bennet; Gail Dawson; Wilson Hu; Connie Leggio; Diane Washington; Russell L Basser Journal: N Engl J Med Date: 2009-09-10 Impact factor: 91.245
Authors: Tino F Schwarz; Thomas Horacek; Markus Knuf; Hanns-Gerd Damman; François Roman; Mamadou Dramé; Paul Gillard; Wolfgang Jilg Journal: Vaccine Date: 2009-10-23 Impact factor: 3.641
Authors: J Garcia-Sicilia; P Gillard; A Carmona; J C Tejedor; J Aristegui; J M Merino; U Behre; A Caplanusi; T Vaman; I Dieussaert Journal: Vaccine Date: 2011-04-17 Impact factor: 3.641
Authors: Nick J Andrews; Woolf T Walker; Adam Finn; Paul T Heath; Andrew C Collinson; Andrew J Pollard; Matthew D Snape; Saul N Faust; Pauline A Waight; Katja Hoschler; Liz Sheasby; Claire Waddington; Simon Kerridge; Jeremy Chalk; Amanda Reiner; Tessa John; Margaret Fletcher; Ruth Allen; Natalie Fineman; Su Wilkins; Michelle Casey; Louise Michaelis; Clarissa Oeser; Ifeanyichukwu Okike; Shamez Ladhani; Elizabeth Miller Journal: Vaccine Date: 2011-08-27 Impact factor: 3.641
Authors: Lisa A Jackson; Shital M Patel; Geeta K Swamy; Sharon E Frey; C Buddy Creech; Flor M Munoz; Raul Artal; Wendy A Keitel; Diana L Noah; Carey Rodeheffer Petrie; Mark Wolff; Kathryn M Edwards Journal: J Infect Dis Date: 2011-09-15 Impact factor: 5.226
Authors: Joanne M Langley; George Risi; Michael Caldwell; Larry Gilderman; Bruce Berwald; Charles Fogarty; Terry Poling; Dennis Riff; Mira Baron; Louise Frenette; Eric Sheldon; Harry Collins; Marc Shepard; Marc Dionne; Daniel Brune; Linda Ferguson; David Vaughn; Ping Li; Louis Fries Journal: J Infect Dis Date: 2011-06-15 Impact factor: 5.226
Authors: Larry R Smith; Walter Wodal; Brian A Crowe; Astrid Kerschbaum; Peter Bruehl; Michael G Schwendinger; Helga Savidis-Dacho; Sean M Sullivan; Mark Shlapobersky; Jukka Hartikka; Alain Rolland; P Noel Barrett; Otfried Kistner Journal: Hum Vaccin Immunother Date: 2013-03-06 Impact factor: 3.452
Authors: Sharon E Frey; David I Bernstein; Rebecca C Brady; Wendy A Keitel; Hana El Sahly; Nadine Georges Rouphael; Mark J Mulligan; Robert L Atmar; Srilatha Edupuganti; Shital M Patel; Michelle Dickey; Irene Graham; Edwin L Anderson; Diana L Noah; Heather Hill; Mark Wolff; Robert B Belshe Journal: Vaccine Date: 2014-11-11 Impact factor: 3.641
Authors: Sinthujan Jegaskanda; Thakshila H Amarasena; Karen L Laurie; Hyon-Xhi Tan; Jeff Butler; Matthew S Parsons; Sheilajen Alcantara; Janka Petravic; Miles P Davenport; Aeron C Hurt; Patrick C Reading; Stephen J Kent Journal: J Virol Date: 2013-10-09 Impact factor: 5.103